The overall prevalence of TDR was 10.1 % , more commonly to nonnucleoside reverse transcriptase inhibitors ( 4.5 % ) and nucleoside reverse transcriptase inhibitors ( 4 % ) compared with protease inhibitors ( 2.8 % ) .